Drug Profile

HY 074

Alternative Names: HY-074; HY-CVS-074

Latest Information Update: 04 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hyloris Pharmaceuticals
Class Antiplatelets; Cardiovascular therapies
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes - Heart failure

Highest Development Phases

Preclinical Acute coronary syndromes

Most Recent Events

04 Mar 2025 Preclinical development in Acute coronary syndromes is underway in Belgium (IV)(Hyloris Pharmaceuticals pipeline, March 2025).
28 Jul 2024 No recent reports of development identified for preclinical development in Acute coronary syndromes in Belgium (IV)
14 Mar 2024 Hyloris Pharmaceuticals files for patent protection for HY-074 in multiple countries prior to March 2024 (IV formulation)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com